Stocktoria
China SXT Pharmaceuticals, Inc. SXTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-01-04
China SXT Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% |
| Operating margin | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% |
| Net margin | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% |
| Return on assets | -15.2% | -13.4% | -20.1% | -17.1% | -8.0% |
| Return on equity | -21.4% | -22.2% | -40.4% | -35.7% | -17.2% |
| Debt / equity | 0.38× | 0.33× | 0.01× | — | 0.00× |
| Current ratio | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 |
| Revenue growth | -9.7% | -2.2% | -24.2% | -45.5% | -7.5% |
Source: SEC EDGAR filings · CIK 0001723980 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.